These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29055564)

  • 1. The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.
    Schneiders FL; Huijts CM; Reijm M; Bontkes HJ; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Immunobiology; 2018 Feb; 223(2):171-177. PubMed ID: 29055564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
    Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation.
    Ferlazzo V; Sferrazza C; Caccamo N; Di Fede G; Di Lorenzo G; D'Asaro M; Meraviglia S; Dieli F; Rini G; Salerno A
    Int J Immunopathol Pharmacol; 2006; 19(2):309-17. PubMed ID: 16831298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S; Chiplunkar SV
    Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-18 activates Vγ9Vδ2
    Murday AS; Chaudhry S; Pauza CD
    Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
    Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
    J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Mattarollo SR; Kenna T; Nieda M; Nicol AJ
    Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
    Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
    Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression.
    Li X; Lu H; Gu Y; Zhang X; Zhang G; Shi T; Chen W
    Exp Cell Res; 2020 Jan; 386(1):111719. PubMed ID: 31726050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.